Literature DB >> 993795

Treatment of benign intracranial hypertension by dehydrating agents with particular reference to the measurement of the blind spot area as a means of recording improvement.

A Jefferson, J Clark.   

Abstract

A series of 30 patients (28 females : 2 males) presenting with benign intracranial hypertension is reported. It is shown that the papilloedema may be resolved in as little as six weeks by the use of dehydration therapy. Evidence is presented that this method can restore to normal a visual acuity which is as low as 6/24 or even 6/36. It is concluded that surgery is never required in the management of this condition. It is strongly recommended that serial blind-spot measurements should be used routinely to assess the effectiveness of therapy. Fluorescein angiography has a place in diagnosis among a small proportion of these patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993795      PMCID: PMC492391          DOI: 10.1136/jnnp.39.7.627

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  PATHOGENESIS OF OEDEMA OF THE OPTIC DISC (PAPILLOEDEMA). A PRELIMINARY REPORT.

Authors:  S S HAYREH
Journal:  Br J Ophthalmol       Date:  1964-10       Impact factor: 4.638

2.  BENIGN INTRACRANIAL HYPERTENSION. VI. OBESITY.

Authors:  M GREER
Journal:  Neurology       Date:  1965-04       Impact factor: 9.910

3.  Benign forms of intracranial hypertension; toxic and otitic hydrocephalus.

Authors:  J FOLEY
Journal:  Brain       Date:  1955       Impact factor: 13.501

4.  [Changes in the blind spot of the fundus oculi in hypertension].

Authors:  V I SHUMILOVA
Journal:  Sov Med       Date:  1962-02

5.  [On the method of registration and measurement of the blind spot].

Authors:  E I USTINOVA
Journal:  Vestn Oftalmol       Date:  1962 Mar-Apr

6.  Pseudotumor cerebri.

Authors:  R PATERSON; N DEPASQUALE; S MANN
Journal:  Medicine (Baltimore)       Date:  1961-02       Impact factor: 1.889

7.  INTRACRANIAL PRESSURE WITHOUT BRAIN TUMOR: DIAGNOSIS AND TREATMENT.

Authors:  W E Dandy
Journal:  Ann Surg       Date:  1937-10       Impact factor: 12.969

8.  Benign intracranial hypertension. I. Diagnosis and prognosis.

Authors:  I Johnston; A Paterson
Journal:  Brain       Date:  1974-06       Impact factor: 13.501

9.  The endocrinological aspects of benign intracranial hypeertension.

Authors:  M B Oldstone
Journal:  Arch Neurol       Date:  1966-10

10.  Fluorescein fundus photography in the detection of early papilloedema and its differentiation from pseudo-papilloedema.

Authors:  S J Miller; M D Sanders; T Ffytche
Journal:  Lancet       Date:  1965-10-02       Impact factor: 79.321

View more
  6 in total

1.  Idiopathic Intracranial Hypertension.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.

Authors:  Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  Benign intracranial hypertension vs. intracranial arteriovenous malformation: a possible CT dilemma.

Authors:  A Spallone
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

4.  A blind spot tester.

Authors:  E Arbit; R L Ruff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-01       Impact factor: 10.154

5.  Medical and surgical management of idiopathic intracranial hypertension in pregnancy.

Authors:  Rosa A Tang; E Ulysses Dorotheo; Jade S Schiffman; Hasan M Bahrani
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

6.  Benign intracranial hypertension: visual loss and optic nerve sheath fenestration.

Authors:  R S Knight; A R Fielder; J L Firth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-03       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.